Shots:
- BI & Tessellate Bio have entered into a research collaboration & global license agreement to develop oral therapies for ALT-positive tumors
- As per the terms, Tessellate Bio will receive near term payments incl. an upfront license fee, research funding & technical milestones along with downstream success-based milestones, making it an aggregate of ~$573M (~€500M)
- Collaboration will focus on developing oral precision therapies for ALT-positive tumors, where blocking the target induces DNA damage, replication stress, & selective tumor cell death in ALT-positive cells
Ref: Boehringer Ingelheim | Image: BI & Tessellate Bio
Related News:- Cue Biopharma Collaborates with Boehringer Ingelheim to Develop B cell-Targeting Bispecifics for Autoimmune and Inflammatory Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
